| scholarly article | Q13442814 |
| P50 | author | Lao H Saal | Q37374892 |
| Man-Hung Eric Tang | Q47503122 | ||
| Danielle van Westen | Q67251674 | ||
| Sofia Gruvberger | Q73510071 | ||
| P2093 | author name string | Anthony George | |
| Åke Borg | |||
| Pär-Ola Bendahl | |||
| Christof Winter | |||
| Christian Ingvar | |||
| Lisa Rydén | |||
| Mårten Fernö | |||
| Ralph Schulz | |||
| Carsten Rose | |||
| Dorthe Grabau | |||
| Helena Jernström | |||
| Jillian Howlin | |||
| Yilun Chen | |||
| Eleonor Olsson | |||
| Malin Dahlgren | |||
| P2860 | cites work | Sequence analysis of mutations and translocations across breast cancer subtypes | Q34032470 |
| Hazard of recurrence among women after primary breast cancer treatment--a 10-year follow-up using data from SEER-Medicare | Q34198900 | ||
| Detection of minimal residual disease | Q34305209 | ||
| Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. | Q34468080 | ||
| Neoplastic characteristics of the DNA found in the plasma of cancer patients | Q34543792 | ||
| Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors | Q35132293 | ||
| Breast cancer, version 3.2013: featured updates to the NCCN guidelines | Q37709567 | ||
| Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. | Q37778114 | ||
| Genomics and the continuum of cancer care | Q37832479 | ||
| Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients | Q39877158 | ||
| Circulating tumor DNA--ready for prime time? | Q44750163 | ||
| Given breast cancer, is fat better than thin? Impact of the estrogen receptor beta gene polymorphisms | Q45287276 | ||
| Circulating tumour cells in non-metastatic breast cancer: a prospective study | Q47652073 | ||
| Global cancer statistics | Q22241238 | ||
| Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics | Q24595882 | ||
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
| Mutational processes molding the genomes of 21 breast cancers | Q24620915 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| Complex landscapes of somatic rearrangement in human breast cancer genomes | Q24631412 | ||
| High-throughput droplet digital PCR system for absolute quantitation of DNA copy number | Q28251729 | ||
| Whole-genome analysis informs breast cancer response to aromatase inhibition | Q28269291 | ||
| Development of personalized tumor biomarkers using massively parallel sequencing | Q28278819 | ||
| Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing | Q28280303 | ||
| Circulating mutant DNA to assess tumor dynamics | Q28289337 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Circos: an information aesthetic for comparative genomics | Q29547653 | ||
| The landscape of cancer genes and mutational processes in breast cancer | Q29614637 | ||
| Analysis of circulating tumor DNA to monitor metastatic breast cancer | Q29614797 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| ROCR: visualizing classifier performance in R | Q29615821 | ||
| Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution | Q29619477 | ||
| Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 | ||
| Advances in understanding cancer genomes through second-generation sequencing | Q30014827 | ||
| A comparative investigation of methods for logistic regression with separated or nearly separated data | Q31059053 | ||
| An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 | ||
| Detection of cancer DNA in plasma of patients with early-stage breast cancer. | Q33624889 | ||
| Circulating tumor cells predict survival in early average-to-high risk breast cancer patients | Q33958981 | ||
| P433 | issue | 8 | |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 1034-1047 | |
| P577 | publication date | 2015-08-01 | |
| P1433 | published in | EMBO Molecular Medicine | Q15817279 |
| P1476 | title | Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease | |
| P478 | volume | 7 |
| Q90259957 | A framework for the development of effective anti-metastatic agents |
| Q37423988 | A genomic case study of desmoplastic small round cell tumor: comprehensive analysis reveals insights into potential therapeutic targets and development of a monitoring tool for a rare and aggressive disease. |
| Q38704258 | A headlight on liquid biopsies: a challenging tool for breast cancer management. |
| Q91839471 | Analysis of solid tumor mutation profiles in liquid biopsy |
| Q37662347 | Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells |
| Q91809618 | Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer Patients |
| Q48118462 | Association of urinary and plasma DNA in early breast cancer patients and its links to disease relapse. |
| Q92982939 | Breast Cancer Recurrence Risk Assessment: Is Non-Invasive Monitoring an Option? |
| Q62132626 | CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy |
| Q57042577 | Can urinary biomarkers replace cystoscopy? |
| Q47142145 | Cell-Free DNA in Oncology: Gearing up for Clinic |
| Q38824891 | Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. |
| Q38669236 | Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients |
| Q46670174 | Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker |
| Q26750899 | Cell-free circulating tumor DNA in cancer |
| Q38699764 | Cell-free circulating tumour DNA as a liquid biopsy in breast cancer |
| Q94593624 | Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
| Q33632125 | Circulating Tumor DNA as Biomarkers for Cancer Detection |
| Q52601844 | Circulating cell-free DNA for non-invasive cancer management. |
| Q64118502 | Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers |
| Q37456554 | Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma |
| Q64057860 | Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer |
| Q57147396 | Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy |
| Q36359821 | Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study |
| Q89359764 | Circulating tumor DNA dynamically predicts response and/or relapse in patients with hematological malignancies |
| Q38633504 | Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions |
| Q36000778 | Circulating tumor DNA in early-stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse? |
| Q26749417 | Circulating tumor DNA in hepatocellular carcinoma: trends and challenges |
| Q62644766 | Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity |
| Q28073730 | Clinical applications of liquid biopsies in gastrointestinal oncology |
| Q64236586 | Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer |
| Q92864393 | Clinical implications of intratumor heterogeneity: challenges and opportunities |
| Q57143867 | Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy |
| Q37362696 | Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. |
| Q90235046 | Clinical significance of plasma free DNA in patients with non-small cell lung cancer |
| Q35936763 | Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing |
| Q38374623 | Current and Emerging Applications of Droplet Digital PCR in Oncology |
| Q58586693 | Current and future perspectives of liquid biopsies in genomics-driven oncology |
| Q36643142 | Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses |
| Q93006316 | Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment |
| Q96028455 | Detection of ctDNA with Personalized Molecular Barcode NGS and Its Clinical Significance in Patients with Early Breast Cancer |
| Q91989229 | Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer |
| Q92408709 | Five Technologies for Detecting the EGFR T790M Mutation in the Circulating Cell-Free DNA of Patients With Non-small Cell Lung Cancer: A Comparison |
| Q33807896 | Fluorescence Lifetime Imaging Microscopy, a Novel Diagnostic Tool for Metastatic Cell Detection in the Cerebrospinal Fluid of Children with Medulloblastoma |
| Q58614975 | Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when? |
| Q90664639 | Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers |
| Q91194970 | Highlighting the uniqueness in dielectrophoretic enrichment of circulating tumor cells |
| Q40385437 | Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. |
| Q96022696 | Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer |
| Q48585692 | Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review |
| Q47563363 | Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System? |
| Q36846985 | KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients |
| Q64064539 | Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients |
| Q37628173 | Liquid Biopsies for Cancer: Coming to a Patient near You. |
| Q58704141 | Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring |
| Q90470736 | Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer |
| Q49740946 | Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer |
| Q49728493 | Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer |
| Q39149201 | Liquid biopsies come of age: towards implementation of circulating tumour DNA. |
| Q91845060 | Liquid biopsy and minimal residual disease - latest advances and implications for cure |
| Q60301685 | Liquid biopsy for pediatric central nervous system tumors |
| Q90322849 | Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology |
| Q58695249 | Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology |
| Q39279845 | Liquid biopsy: unlocking the potentials of cell-free DNA. |
| Q47630582 | Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse |
| Q47104315 | Mechanistic signatures of HPV insertions in cervical carcinomas |
| Q33865098 | Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events |
| Q48229387 | Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. |
| Q38756841 | Molecular pathology in real time |
| Q57636579 | Neueste technologische Entwicklungen für die Analyse von zirkulierender Tumor-DNA |
| Q33866887 | Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy |
| Q38700222 | Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies |
| Q38885953 | Noninvasive strategies for breast cancer early detection. |
| Q48138460 | Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. |
| Q48685076 | Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary |
| Q60312883 | Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer |
| Q53199357 | Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy. |
| Q98289701 | Potential value of circulating tumor DNA in gynecological tumors |
| Q38816994 | Powerful qPCR assays for the early detection of latent invaders: interdisciplinary approaches in clinical cancer research and plant pathology |
| Q100764047 | Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies |
| Q55379220 | Precision Medicine in Hormone Receptor-Positive Breast Cancer. |
| Q39116735 | Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer |
| Q92152629 | Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA |
| Q59714916 | Profiling circulating tumour cells and other biomarkers of invasive cancers |
| Q57106079 | Progress in adjuvant systemic therapy for breast cancer |
| Q37110941 | Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers |
| Q36545690 | Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing |
| Q26777395 | Revealing the Complexity of Breast Cancer by Next Generation Sequencing |
| Q90664778 | Review ctDNA and Breast Cancer |
| Q42687570 | Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring |
| Q41620161 | Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. |
| Q37123931 | Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic |
| Q58578019 | Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management |
| Q89018078 | The Utility of Liquid Biopsy in Central Nervous System Malignancies |
| Q64062553 | The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer |
| Q39183864 | The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring |
| Q64112101 | The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis |
| Q55269325 | The potential of liquid biopsies for the early detection of cancer. |
| Q38825179 | The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring |
| Q37407810 | The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies |
| Q53790103 | The tumour trail left in blood. |
| Q64102949 | Translating insights into tumor evolution to clinical practice: promises and challenges |
| Q30251738 | Translating neoadjuvant therapy into survival benefits: one size does not fit all. |
| Q90724935 | Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements |
| Q36318892 | Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. |
| Q92642250 | Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment |
| Q90373973 | Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation? |
Search more.